TGTX vs VRTX vs RARE vs ABBV

For growth investors, TG Therapeutics, Inc.

(TGTX) is the stronger pick with 87. 3% revenue growth year-over-year, versus 8. 6% for AbbVie Inc. (ABBV). TG Therapeutics, Inc. (TGTX) offers the better valuation at 15. 5x trailing P/E (32. 3x forward), making it the more compelling value choice. Analysts rate TG Therapeutics, Inc. (TGTX) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, TG Therapeutics, Inc.

(TGTX) is the cheapest at 15. 5x versus AbbVie Inc. at 85. 5x. On forward P/E, AbbVie Inc. is actually cheaper at 14. 3x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +101. 3%, compared to -77. 2% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: TGTX returned +436. 5% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Ultragenyx Pharmaceutical Inc. 's 1. 42β — meaning RARE is approximately 319% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Vertex Pharmaceuticals Incorporated (VRTX) carries a lower debt/equity ratio of 21% versus 40% for TG Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TG Therapeutics, Inc.

(TGTX) is pulling ahead at 87. 3% versus 8. 6% for AbbVie Inc. (ABBV). On earnings-per-share growth, the picture is similar: TG Therapeutics, Inc. grew EPS 1747% year-over-year, compared to -0. 8% for AbbVie Inc.. Over a 3-year CAGR, TGTX leads at 504. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TG Therapeutics, Inc.

(TGTX) is the more profitable company, earning 72. 6% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 72. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39. 4% versus -79. 5% for RARE. At the gross margin level — before operating expenses — VRTX leads at 85. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, AbbVie Inc.

(ABBV) trades at 14. 3x forward P/E versus 32. 3x for TG Therapeutics, Inc. — 18. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RARE: 97. 1% to $51. 50.

In this comparison, ABBV (3.

2% yield) pays a dividend. TGTX, VRTX, RARE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Both have compounded well over 10 years (ABBV: +295. 5%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TGTX is a small-cap high-growth stock; VRTX is a mid-cap quality compounder stock; RARE is a small-cap high-growth stock; ABBV is a large-cap income-oriented stock. ABBV pays a dividend while TGTX, VRTX, RARE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.